News | September 02, 2010

STAR-Heart Study Presented at the European Society of Cardiology

September 2, 2010 - The STAR-heart study, which was presented at the European Society of Cardiology 2010 Congress in August 2010, reported that the intracoronary injection of autologous stem cells derived from bone marrow is associated with improved hemodynamics and long term survival in the treatment of chronic heart failure.

Cardiogenesis Corporation released comments today regarding the STAR-heart study. The study involved 391 patients with chronic heart failure due to ischemic cardiomyopathy. Of these patients, 191 accepted the stem-cell treatment while the other 200, who did not agree to the intervention, acted as controls.

Paul McCormick Executive Chairman for Cardiogenesis said, "The positive results of the STAR-heart study reinforce our plan to initiate in the near future clinical studies in which autologous bone marrow cells will be used in conjunction with transmyocardial revascularization (TMR). Although our clinical studies testing delivery of stem cells with the PHOENIX Combination Delivery System will target different patient populations than the STAR study, the STAR study demonstrated the clinical benefit that can be derived from autologous bone marrow cells in patients with heart disease. The use of autologous bone marrow cells is akin to harnessing the combination of biologics that is naturally produced by the body as part of its regenerative process.

He added, "also relevant to our planned studies was the commentary by the STAR study investigators that pre-conditioning of the target myocardium was a key factor in the success of their implanted stem cells. Pre-conditioning in the STAR trial was accomplished by an ischemia-producing stimulus caused by balloon dilatation during the stem cell infusion, which seems to be important for creating an environment for the stem cells to home into the cardiac tissue and improve cell retention. In our clinical studies, PHOENIX will utilize its TMR System to create an environment to maximize cell retention by first treating the target myocardium with TMR, followed by cell injection. Our clinical studies follow on animal (pig) studies that demonstrated increased early cell survival in infarcted tissue when TMR was used as a pre-treatment to stem cell injection. We are optimistic that the combination of TMR plus concentrated bone marrow cells will have a synergistic effect in reducing angina in humans."

The company recently announced its plan to begin enrollment in a feasibility trial for the PHOENIX Combination Delivery System. The results of that ex-US study will be used in support of its FDA submission to begin a pivotal trial in the US.

For more information: www.cardiogenesis.com

Related Content

Secant Introduces First Synthetic Regenerative Cardiovascular Graft for CABG
News | Stem Cell Therapies| January 17, 2018
Secant Group, in partnership with its sister company SanaVita Medical, announced new technology to advance...
News | Stem Cell Therapies| October 24, 2017
October 24, 2017 — Roche and Ncardia have reached a broad licensing agreement whereby Roche and its affiliate compani
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...

An example of porcine cartdiac stem cells. Photo from the University of Miami Miller School of Medicine.

 

News | Stem Cell Therapies| June 12, 2017
June 12, 2017 — Heart muscle is one of the least renewable tissues in the body, which is one of the reasons that hear
Stem Cell Therapy Holds Promise for Treating Most Severe Cases of Angina
News | Stem Cell Therapies| May 12, 2017
An analysis of data from the entire development program consisting of three trials assessing the feasibility of using a...
3-D Printed Patch Can Help Mend a ‘Broken’ Heart

This photo shows the 3D-bioprinted cell patch in comparison to a mouse heart. When the patch was placed on a live mouse following a simulated heart attack, the researchers saw significant increase in functional capacity after just four weeks. Image courtesy of Patrick O’Leary, University of Minnesota.

News | Stem Cell Therapies| April 18, 2017
April 18, 2017 — A team of biomedical engineering researchers, led by the University of Minnesota, has created a revo
Texas Heart Institute, ischemic heart failure, adult stem cell therapy, CONCERT-HF clinical trial
News | Stem Cell Therapies| February 03, 2017
Physicians and researchers at Texas Heart Institute are recruiting patients who suffer from heart failure to...
News | Stem Cell Therapies| January 09, 2017
BioCardia Inc. announced in December the issuance of United States Patent No. 9,517,199 relating to a method of...
Overlay Init